OCT Clinical

Together for a Better Future in Clinical Research! After months of intense negotiations and thoughtful deliberations, we are honored and thrilled to announce a landmark event in our company’s history. On Friday, May 24, 2024, OCT Clinical and palleos healthcare signed the M&A agreement, setting a new benchmark in the European clinical research landscape. We are now united under a single brand name — palleos healthcare! By combining our strengths, both companies are now better positioned to leverage a comprehensive network across a region with a total population of 300 million. This merger goes beyond expansion; it intensifies our joint expertise from pre-clinical consulting to clinical trials, ensuring that our clients receive unparalleled end-to-end services. Special thanks to Philip Raeth, Dmitry Sharov, Anna Yanaeva, and all others involved in making this historic deal possible!   Subscribe to palleos healthcare LinkedIn page as they’ll also be sharing insightful information on the clinical research in Europe! For more details about this agreement, check out our press release: https://lnkd.in/eGfyAxKy or if you have any additional questions, don’t hesitate to contact us at info@oct-clinicaltrials.com or info@palleos.com and we’ll be happy to give you further insights! #clinicalresearch #healthcarenews #merger #octclinical #palleoshealthcare #croeurope #croservices 

Mark these numbers - booth #615, hall #3, #ESMO #2024. Our palleos healthcare team is exhibiting in Barcelona! Make sure to stop by and exhange insights into #oncologyresearch in #EasternEurope Also, subscribe to palleos LI page to stay tuned on updates - more things are coming!

A little of flashbacks to #ESMOCongress 2023! Almost a year ago, OCT Clinical had an unforgettable experience exhibiting at #ESMO in Madrid, Spain. Check out the photos below to relive those moments with our Business Development team and the visitors at our booth! This year, we're geared up for an even more successful event at #ESMO2024 in Barcelona. Thanks to our recent merger with palleos healthcare, our united team is stronger than ever and ready to demonstrate you the joint clinical trials expertise in Eastern and Central Europe. Meet Us at #ESMOCongress2024 in Barcelona from September 13-17, 2024! Feel free to schedule a meeting in advance or drop by Booth #615 to chat with our exhibiing team. Anna Yanaeva Polina Pogudina Philip Raeth See you soon in Barcelona!  ESMO - European Society for Medical Oncology #esmocongress2024 #clinicaltrials #croserviceeurope

We're aware that the recent news about our merge with palleos healthcare has been quite hot. In this regard, we want to offer you some refreshment - just reminding you that OCT's branded #quiz on #clinicaltrials is still there! Unexpectedly it gained so much popularity among our followers! Feel free to click below and check your knowledge on the clinical trials basics! https://lnkd.in/e_kGkY_W

We were thrilled to be part of such a huge event as #BIO2024 in San Diego! While our team is already on the way back from the USA, we're still available to talk about your clinical trials project in Europe! Don't be shy and DM Anna Yanaeva or Philip Raeth about it. We'll surely see you next year! palleos healthcare #croservices #clinicaltrialseurope

The merger deal between OCT and palleos healthcare has received exceptional coverage in major industry media. For example, Fierce Biotech, a leading resource for news on pre-clinical and clinical advancements as well as business trends, has shared this significant event with its readers and subscribers. Check it out too! https://lnkd.in/eGwVNs23

Even though it's been a week since the signing of the deal between palleos healthcare and OCT Clinical, we're still celebrating the exciting developments in the European clinical research industry! Here's a glimpse from last Friday in Frankfurt am Main, Germany, where top management from both companies officially registered the M&A agreement. Subscribe to palleos healthcare and stay tuned for more updates!

Considering the exciting news of the merger agreement between OCT Clinical and palleos healthcare that we disclosed yesterday, we’re ready to announce that American Society of Clinical Oncology (ASCO) is going to be the first public event in which palleos and OCT will take part jointly! Already this Friday, May 31, just a week after signing the deal, we’ll be in Chicago, exhibiting at #ASCO24 with a booth! Representatives from OCT—Anna Yanaeva, Polina Pogudina, Varvara Melnikova — and palleos healthcare Vice President Philip Raeth will be delighted to discuss the opportunities available for conducting oncology trials in the European region. Feel free to schedule a meeting by DMing any member of our team or drop by spontaneously at our booth. By the way, subscribe to @palleoshealthcare because they’ll be broadcasting the insights live from #ASCO24 See you soon in Chicago, USA! 📍

We are happy to announce that this year OCT will be exhibiting with a booth at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, happening May 31 - June 4 in Chicago. 📍 #ASCO is renowned as the leading professional organization for oncology professionals worldwide, and its Annual Meeting stands as the prime event in the oncology field. Join us in connecting with top #oncology professionals from across the globe, forging new collaborations, and helping shape the future of cancer care. Reach out to OCT's Business Development Assistant Varvara Melnikova, at vmelnikova@oct-clinicaltrials.com to schedule a meeting or just show up at our 𝐛𝐨𝐨𝐭𝐡 #37121. See you soon at #ASCO24!

Happy Clinical Trials Day to everyone involved in this industry! Whether you're a participant, researcher, investigator, or partner, this day is significant to the whole industry! On this day in 1747, Scottish physician James Lind performed the first documented in-human trial. Since then, pivotal milestones have shaped global standards in clinical research. For instance, placebo control was introduced in 1800, and in 1947, Dr. Hill in the UK conducted the first randomized trial, showcasing the benefits of randomization over previous methods. Now, randomized, double-blind, and placebo-controlled trials (affectionately known as #RDBPCTs among experts) are considered the gold standard for most research projects. So, in a nutshell: ·    𝑾𝒉𝒚 𝒓𝒂𝒏𝒅𝒐𝒎𝒊𝒛𝒆?  To ensure fair comparisons between new and standard treatments. By randomly assigning treatments to participants, it ensures that each group has similar characteristics, eliminating possible biased results.   ·    𝑾𝒉𝒚 𝒃𝒍𝒊𝒏𝒅𝒊𝒏𝒈?  In a randomized controlled trial, blinding both patients and medical staff to the treatment (or placebo) being administered helps prevent bias from expectations or perceptions. This ensures that any observed effects are due to the treatment itself because, if the treatment is known, patients or doctors may consciously or unconsciously record biased evaluations that do not reflect reality. ·    𝑾𝒉𝒚 𝑷𝒍𝒂𝒄𝒆𝒃𝒐? To prove that a new treatment really works and it's not just a placebo effect, the results from people who got the treatment with those who got a placebo are compared to find out what intervention really works. We hope you find this brief overview helpful! If you have any questions, don’t hesitate to contact us at info@oct-clinicaltrials.com. Our MedSci experts will be delighted to assist you in organizing a trial adhering to modern GCP standards. #clinicaltrialsday #placebo #clinicaltrials #croservices #clinicaltrialseasterneurope #jameslind